 |
 |

December 1, 1999
JAMA. 1999;282:2087-2088.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
Physicians in the United States, Canada, and Mexico
Physicians with current and valid licenses in the United States, Canada, or Mexico who read any 3 of the selected continuing medical education (CME) articles in this issue of JAMA, complete the CME Evaluation Form, and fax it to the number or mail it to the address at the bottom of the CME Evaluation Form are eligible for category 1 CME credit. There is no charge.
The American Medical Association (AMA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor CME for physicians. The AMA designates this educational activity for up to 1 hour of category 1 CME credit per JAMA issue toward the AMA Physician's Recognition Award (PRA). Each physician should claim for credit only those hours that were actually spent in this educational activity.
Physicians in Other Countries
Physicians with current and valid licenses in the United States, Mexico, or Canada are eligible for . . . [Full Text of this Article]
RELATED ARTICLES
Intra-arterial Prourokinase for Acute Ischemic Stroke: The PROACT II Study: A Randomized Controlled Trial
Anthony Furlan, Randall Higashida, Lawrence Wechsler, Michael Gent, Howard Rowley, Carlos Kase, Michael Pessin, Arvind Ahuja, Fred Callahan, Wayne M. Clark, Frank Silver, Frank Rivera, and for the PROACT Investigators
JAMA. 1999;282(21):2003-2011.
ABSTRACT
| FULL TEXT
Low Risk-Factor Profile and Long-term Cardiovascular and Noncardiovascular Mortality and Life Expectancy: Findings for 5 Large Cohorts of Young Adult and Middle-Aged Men and Women
Jeremiah Stamler, Rose Stamler, James D. Neaton, Deborah Wentworth, Martha L. Daviglus, Dan Garside, Alan R. Dyer, Kiang Liu, and Philip Greenland
JAMA. 1999;282(21):2012-2018.
ABSTRACT
| FULL TEXT
Recombinant Tissue-Type Plasminogen Activator (Alteplase) for Ischemic Stroke 3 to 5 Hours After Symptom Onset: The ATLANTIS Study: A Randomized Controlled Trial
Wayne M. Clark, Stanley Wissman, Gregory W. Albers, Jack H. Jhamandas, Kenneth P. Madden, Scott Hamilton, and for the ATLANTIS Study Investigators
JAMA. 1999;282(21):2019-2026.
ABSTRACT
| FULL TEXT
Dietary Sodium Intake and Subsequent Risk of Cardiovascular Disease in Overweight Adults
Jiang He, Lorraine G. Ogden, Suma Vupputuri, Lydia A. Bazzano, Catherine Loria, and Paul K. Whelton
JAMA. 1999;282(21):2027-2034.
ABSTRACT
| FULL TEXT
Hemodynamic Shear Stress and Its Role in Atherosclerosis
Adel M. Malek, Seth L. Alper, and Seigo Izumo
JAMA. 1999;282(21):2035-2042.
ABSTRACT
| FULL TEXT
Preventing Coronary Artery Disease by Lowering Cholesterol Levels: Fifty Years From Bench to Bedside
Daniel Steinberg and Antonio M. Gotto, Jr
JAMA. 1999;282(21):2043-2050.
ABSTRACT
| FULL TEXT
An Evidence-Based Assessment of the NCEP Adult Treatment Panel II Guidelines
Benjamin J. Ansell, Karol E. Watson, and Alan M. Fogelman
JAMA. 1999;282(21):2051-2057.
ABSTRACT
| FULL TEXT
Oral Anticoagulant Therapy in Patients With Coronary Artery Disease: A Meta-analysis
Sonia S. Anand and Salim Yusuf
JAMA. 1999;282(21):2058-2067.
ABSTRACT
| FULL TEXT
Chlamydia pneumoniae and Atherosclerosis
Allan Shor and James I. Phillips
JAMA. 1999;282(21):2071-2073.
EXTRACT
| FULL TEXT
|